Establishing and Externally Validating a Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score-Based Nomogram for Predicting Early Recurrence in BCLC Stage 0/A Hepatocellular Carcinoma Patients After Radical Liver Resection: A Multi-Center Study
Xulin Liu,Zhancheng Qiu,Elijah Ndhlovu,Yunyan Wan,Huapeng Sun,Shuai Wang,Yugang Cao,Peng Zhu
DOI: https://doi.org/10.2147/jhc.s465670
2024-06-15
Journal of Hepatocellular Carcinoma
Abstract:Xulin Liu, 1, &ast Zhancheng Qiu, 2, &ast Elijah Ndhlovu, 1, &ast Yunyan Wan, 3 Huapeng Sun, 4 Shuai Wang, 5 Yugang Cao, 6 Peng Zhu 1 1 Department of Hepatic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China; 2 Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People's Republic of China; 3 Department of Hepatobiliary Pancreatic Surgery, Taihe Hospital, Shiyan City, Hubei Province, People's Republic of China; 4 Department of General Surgery, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, People's Republic of China; 5 Department of Hepatobiliary Surgery, Jingzhou Central Hospital, Jingzhou, People's Republic of China; 6 Department of Hepatobiliary and Pancreatic Surgery, Huangshi Central Hospital of Edong Healthcare Group, Huangshi, People's Republic of China &astThese authors contributed equally to this work Correspondence: Peng Zhu, Department of Hepatic Surgery, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China, Tel +86 13907170712, Email Purpose: Early recurrence (ER) is associated with poor prognosis in hepatocellular carcinoma (HCC). In this study, we developed and externally validated a nomogram based on the hemoglobin, albumin, lymphocytes, and platelets (HALP) score to predict ER for patients with BCLC stage 0/A HCC who underwent radical liver resection. Patients and Methods: A total of 808 BCLC stage 0/A HCC patients from six hospitals were included in this study, and they were assigned to a training cohort (n = 500) and an external validation cohort (n = 308). We used univariate and multivariate Cox regression analysis to identify the independent risk factors for disease-free survival (DFS). We also established and externally validated a nomogram based on these risk predictors. The nomogram was evaluated using the area under the receiver operating characteristic curve (AUC), the concordance index (C-index), the calibration curve, decision curve analysis (DCA), and Kaplan‒Meier analysis. Results: Multivariate COX regression showed that HBV DNA ≥ 10,000 IU/mL (P < 0.001), HALP score ≤ 38.20 (P < 0.001), tumor size (P = 0.003), clinically significant portal hypertension (P = 0.001), Edmondson-Steiner grade (III–IV) (P = 0.007), satellite nodules (P < 0.001), and MVI (P = 0.001) were independent risk factors for post-operative tumor recurrence. The AUC of our nomogram for predicting the 2-year and 5-year DFS was 0.756 and 0.750, respectively, in the training cohort and 0.764 and 0.705, respectively, in the external validation cohort. We divided the patients into low-, intermediate- and high-risk groups according to the risk score calculated by the nomogram. There were statistically significant differences in the DFS and overall survival (OS) among the three groups of patients (P < 0.001). Conclusion: We developed and externally validated a new nomogram, which is accurate and can predict ER in BCLC stage 0/A HCC patients after curative liver resection. Keywords: early recurrence, hepatocellular carcinoma, HALP score, nomogram, Barcelona Clinic of Liver Cancer staging system, disease-free survival As of 2022, primary liver cancer was the sixth most diagnosed cancer and the third leading cause of cancer-related death in the world, with about 865,000 new cases and 757,948 deaths. 1 75–85% of primary liver cancer is hepatocellular carcinoma (HCC). 1 For patients with Barcelona Clinic Liver Cancer (BCLC) stage 0/A HCC, hepatectomy is the most effective treatment method. 2,3 However, even after active surgical treatment, the prognosis of HCC patients remains poor due to high recurrence rates. The 5-year recurrence rate after radical hepatectomy is as high as 50–70%. 4,5 Recurrence within two years of liver resection (LR) is defined as early recurrence (ER). 6 Compared with late recurrence, patients with ER have poor tumor biology and worse prognoses. 6,7 Therefore, identifying the risk factors for HCC recurrence, especially ER, and providing early post-operative adjuvant therapy for high-risk patients will be beneficial in improving their prognoses. Currently, multiple nomograms exist to predict HCC recurrence. However, they encompass a broad spectrum of tumor stages, including advanced stages such as BCLC stage C and TNM stage IV, leading to imprecise prognostic predi -Abstract Truncated-
oncology